Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Three Abstracts From Advaxis, Inc. (ADXS) Accepted For Presentation At Society For Immunotherapy Of Cancer Annual Meeting

|Includes: Advaxis Inc. (ADXS)

Advaxis, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, was pleased to announce today that three abstracts describing research with Advaxis Lm-LLO immunotherapies have been selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 28th Annual Meeting. This year's meeting will take place November 8-10, 2013, at the Gaylord National Hotel & Convention Center in National Harbor, MD.

The abstract titled "Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment" has been selected for oral presentation during the session, "Tumor Microenvironment and Innate Cells Recognition" on November 8, 2013 from 9:40 AM to 12:00 PM. Anu Wallecha, Ph.D., Director of Research and Development at Advaxis, will report on the localized effects of Lm-LLO immunotherapies on the tumor microenvironment in preclinical studies using transplantable mouse models.

The abstract titled "ADXS11-001 immunotherapy targeting HPV-E7: Updated survival and safety data from a Phase 2 study in Indian women with recurrent/refractory cervical cancer" has been selected for poster presentation during the Vaccine session. Robert Petit, Ph.D., Chief Scientific Officer of Advaxis, will present final 18-month survival and updated safety data from the ongoing trial.

The abstract titled "Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy" has been selected for poster presentation during the session "Biomarkers and Immunoscoring". Poonam Molli, Ph.D., Senior Scientist at Advaxis, will report on the correlation of changes in cytokine and chemokine levels pre- and post-dosing with ADXS11-001 from the Phase 2 study in Indian women with recurrent/refractory cervical cancer.

"The three presentations of Advaxis data at SITC reflect our growing understanding of the unique attributes of the Advaxis platform technology for immunotherapies. Dr. Wallecha's presentation will highlight the ability of Lm-LLO immunotherapy to counteract immune suppressor cells that enable persistence of the tumor. We will report final 18-month survival and final tumor response data from our 110 patient Phase 2 study in India in women with recurrent cervical cancer. Dr. Molli's presentation will illustrate the remarkable immune stimulation that occurs in patients after treatment with ADXS11-001. Together, these data paint a picture of an immunotherapy that has a strong positive impact on the immune system while at the same time counteracting immune suppression in the tumor microenvironment that can lead to apparent prolonged survival and objective tumor responses from a single immunotherapeutic agent," commented Dr. Petit.

For additional information, please visit: ADXS.MissionIR.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net